Background
A critical treatment gap exists in SLE management: hydroxychloroquine (~$6/month) serves as the universal backbone therapy, but the next escalation step jumps to expensive biologics (belimumab, anifrolumab) costing thousands per month — largely inaccessible in low- and middle-income countries. An affordable intermediate option targeting the underlying metabolic dysfunction in lupus T-cells is urgently needed.
Hypothesis
In SLE patients with incomplete disease control on hydroxychloroquine, adding low-dose sirolimus (1–2 mg/day) plus metformin (500–1000 mg/day) will achieve superior restoration of T-cell metabolic homeostasis — measured by normalization of mitochondrial membrane potential and reversal of the Th17/Treg ratio — compared to hydroxychloroquine monotherapy alone.
Mechanistic Rationale
Lupus T-cells exhibit constitutive mTORC1 hyperactivation, driving HRES-1/Rab4 GTPase overexpression, TCRζ chain loss, and enhanced calcium signalling. Sirolimus directly reverses mTOR hyperactivity and normalizes downstream S6K1/4E-BP1 phosphorylation in lupus T-cells. Metformin inhibits mitochondrial complex I, activates AMPK, and suppresses mTOR through a complementary pathway — creating convergent metabolic reprogramming. Proof-of-concept from oncology shows that sirolimus + metformin combination in CAR-T cells induces AMPK activation, PGC-1α induction, and enhanced mitochondrial spare respiratory capacity, suggesting synergistic effects translatable to lupus T-cell biology.
Novelty
No clinical trial has tested the triple combination. A Phase 1 stud





























